| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Roche Holding AG (MX: ROGN)
ROGN Technical Analysis
5
| As on 9th Jun 2023 ROGN STOCK Price closed @ 5342.13 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 7545.85 & Strong Sell for SHORT-TERM with Stoploss of 7814.59 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ROGNSTOCK Price
| Open | 5431.78 | Change | Price | % |
| High | 5431.78 | 1 Day | -174.33 | -3.16 |
| Low | 5342.13 | 1 Week | -355.93 | -6.25 |
| Close | 5342.13 | 1 Month | 174.19 | 3.37 |
| Volume | 251 | 1 Year | -2484.74 | -31.75 |
| 52 Week High 8541.36 | 52 Week Low 5167.94 | ||||
MX Mexico Most Active Stocks
| AMXL | 19.28 | -0.36% |
| CEMEXCPO | 12.06 | 0.58% |
| GIGANTE | 19.67 | -6.11% |
| HCITY | 7.78 | 3.73% |
| WALMEX | 67.47 | -1.10% |
| FR | 439.66 | 0.34% |
| KIMBERA | 38.43 | 0.63% |
| GFNORTEO | 140.87 | 0.90% |
| FUNO11 | 25.73 | 0.74% |
| GMEXICOB | 85.38 | 1.51% |
MX Mexico Top Gainers Stocks
MX Mexico Top Losers Stocks
| ROGN Daily Charts |
ROGN Intraday Charts |
Whats New @ Bazaartrend |
ROGN Free Analysis |
|
|
ROGN Important Levels Intraday
| RESISTANCE | 5514.89 |
| RESISTANCE | 5459.48 |
| RESISTANCE | 5425.24 |
| RESISTANCE | 5390.99 |
| SUPPORT | 5293.27 |
| SUPPORT | 5259.02 |
| SUPPORT | 5224.78 |
| SUPPORT | 5169.37 |
ROGN Forecast May 2024
| 4th UP Forecast | 6918.88 |
| 3rd UP Forecast | 6413.21 |
| 2nd UP Forecast | 6100.64 |
| 1st UP Forecast | 5788.07 |
| 1st DOWN Forecast | 4896.19 |
| 2nd DOWN Forecast | 4583.62 |
| 3rd DOWN Forecast | 4271.05 |
| 4th DOWN Forecast | 3765.38 |
ROGN Weekly Forecast
| 4th UP Forecast | 5539.63 |
| 3rd UP Forecast | 5476.29 |
| 2nd UP Forecast | 5437.14 |
| 1st UP Forecast | 5397.99 |
| 1st DOWN Forecast | 5286.27 |
| 2nd DOWN Forecast | 5247.12 |
| 3rd DOWN Forecast | 5207.97 |
| 4th DOWN Forecast | 5144.63 |
ROGN Forecast2024
| 4th UP Forecast | 11842.7 |
| 3rd UP Forecast | 9757.94 |
| 2nd UP Forecast | 8469.29 |
| 1st UP Forecast | 7180.64 |
| 1st DOWN Forecast | 3503.62 |
| 2nd DOWN Forecast | 2214.97 |
| 3rd DOWN Forecast | 926.32 |
| 4th DOWN Forecast | -1158.45 |
Roche Holding AG ( MX Mexico Symbol : ROGN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ROGN Business Profile
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick's samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland. Address: Konzern Hauptsitz, Basel, Switzerland, 4070
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service